FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W60939811> ?p ?o ?g. }

• W60939811 abstract "Background and aims Patients with established cardiovascular disease or diabetes mellitus type 2 (DM2) are likely to receive separate treatment of an aspirin, a statin and blood pressure (BP)-lowering agents. Combining these pharmacological agents into a cardiovascular polypill, could be considered in these patients to reduce prescription gaps and increase adherence. We evaluated the effect of the concomitant use of aspirin, a statin and BP-lowering agent(s) in patients with vascular diseases or DM2 on vascular morbidity and mortality in current clinical practice. Methods In total 5783 patients with coronary artery disease, cerebrovascular disease, abdominal aortic aneurysm, peripheral arterial occlusive disease or DM2 enrolled in the Second Manifestations of ARTerial disease study were followed/up for the occurerence of a subsequent vascular event (i.e. myocardial infarction (MI), ischaemic cerebrovascular accident (iCVA), vascular death), composite vascular endpoint (combination of previous mentioned) and all-cause mortality. Results In total 2456 (42%) used aspirin, a statin and 1 BP lowering agent. During a median of 5.3 years (interquartile range 2.7-9.3 years), 758 patients experienced a new vascular event and 737 died. Combination therapy with aspirin, statin and ≥1 BP lowering agent was associated with a lower risk of MI (HR 0.77; 95%CI 0.62-0.97), iCVA (HR 0.75; 95%CI 0.52-1.08), vascular mortality (HR 0.56; 95%CI 0.44-0.72), composite vascular endpoint (HR 0.52; 95%CI 0.43-0.63) and all-cause mortality (HR 0.52; 95%CI 0.43-0.63) after adjusting for confounding covariates ( Table 1 ). Table Aspirin, statin and ≥1 BP lowering agents Study endpoint No. of events HR (95%-CI) Coronary Artery Disease I 418 0,79 (0,63-0,97) II 0,77 (0,62-0,95) III 0,77 (0,62-0,95) IV 0,79 (0,63-0,99) PS 0,77 (0,62-0,97) Cerebrovascular accident I 181 0,65 (0,46-0,91) II 0,64 (0,46-0,90) III 0,65 (0,46-0,91) IV 0,78 (0,54-1,13) PS 0,75 (0,52-1,08) Composite Vascular Endpoint I 720 0,73 (0,62-0,86) II 0,72 (0,61-0,85) III 0,73 (0,61-0,86) IV 0,78 (0,65-0,94) PS 0,75 (0,62-0,89) Vascular Mortality I 428 0,59 (0,47-0,75) II 0,62 (0,49-0,78) III 0,60 (0,48-0,76) IV 0,63 (0,49-0,80) PS 0,56 (0,44-0,72) All-cause Mortality I 737 0,54 (0,45-0,65) II 0,56 (0,47-0,67) III 0,56 (0,47-0,68) IV 0,57 (0,47-0,69) PS 0,52 (0,43-0,63) Model I: Crude II: Adjusted for gender, age III: II + additional adjustment for BMI, current smoking, packyears, concommitent cardiovascular disease IV: III + additional adjustment for LDL, systolic BP Propensity Score: composed of gender, age, BMI, current smoking, packyears, concomitant cardiovascular disease, LDL cholesterol and systolic BP Conclusion The combined use of aspirin, statin and at least 1 BP lowering agent was associated with a lower risk of vascular morbidity and mortality in patients with established cardiovascular disease or DM2. Introduction of a polypill in these high risk patients may promote the use of preventive pharmacologic treatment and contribute to better adherence thereby decreasing the risk for vascular morbidity and mortality." @default.
• W60939811 created "2016-06-24" @default.
• W60939811 creator A5007679161 @default.
• W60939811 creator A5011326007 @default.
• W60939811 creator A5022335989 @default.
• W60939811 creator A5041370264 @default.
• W60939811 creator A5077863525 @default.
• W60939811 date "2012-03-13" @default.
• W60939811 modified "2023-09-24" @default.
• W60939811 title "Abstract P329: The Use of Polypill Components is Related to Lower Vascular Morbidity Aand Mortality in Patients With Vascular Diseases or Type 2 Diabetes Mellitus" @default.
• W60939811 doi "https://doi.org/10.1161/circ.125.suppl_10.ap329" @default.
• W60939811 hasPublicationYear "2012" @default.
• W60939811 type Work @default.
• W60939811 sameAs 60939811 @default.
• W60939811 citedByCount "0" @default.
• W60939811 crossrefType "journal-article" @default.
• W60939811 hasAuthorship W60939811A5007679161 @default.
• W60939811 hasAuthorship W60939811A5011326007 @default.
• W60939811 hasAuthorship W60939811A5022335989 @default.
• W60939811 hasAuthorship W60939811A5041370264 @default.
• W60939811 hasAuthorship W60939811A5077863525 @default.
• W60939811 hasConcept C119060515 @default.
• W60939811 hasConcept C126322002 @default.
• W60939811 hasConcept C127413603 @default.
• W60939811 hasConcept C134018914 @default.
• W60939811 hasConcept C141071460 @default.
• W60939811 hasConcept C164705383 @default.
• W60939811 hasConcept C2776839432 @default.
• W60939811 hasConcept C2777466421 @default.
• W60939811 hasConcept C2777628954 @default.
• W60939811 hasConcept C2777758740 @default.
• W60939811 hasConcept C2778213512 @default.
• W60939811 hasConcept C2780645631 @default.
• W60939811 hasConcept C500558357 @default.
• W60939811 hasConcept C555293320 @default.
• W60939811 hasConcept C71924100 @default.
• W60939811 hasConcept C78519656 @default.
• W60939811 hasConceptScore W60939811C119060515 @default.
• W60939811 hasConceptScore W60939811C126322002 @default.
• W60939811 hasConceptScore W60939811C127413603 @default.
• W60939811 hasConceptScore W60939811C134018914 @default.
• W60939811 hasConceptScore W60939811C141071460 @default.
• W60939811 hasConceptScore W60939811C164705383 @default.
• W60939811 hasConceptScore W60939811C2776839432 @default.
• W60939811 hasConceptScore W60939811C2777466421 @default.
• W60939811 hasConceptScore W60939811C2777628954 @default.
• W60939811 hasConceptScore W60939811C2777758740 @default.
• W60939811 hasConceptScore W60939811C2778213512 @default.
• W60939811 hasConceptScore W60939811C2780645631 @default.
• W60939811 hasConceptScore W60939811C500558357 @default.
• W60939811 hasConceptScore W60939811C555293320 @default.
• W60939811 hasConceptScore W60939811C71924100 @default.
• W60939811 hasConceptScore W60939811C78519656 @default.
• W60939811 hasIssue "suppl_10" @default.
• W60939811 hasLocation W609398111 @default.
• W60939811 hasOpenAccess W60939811 @default.
• W60939811 hasPrimaryLocation W609398111 @default.
• W60939811 hasRelatedWork W1994233110 @default.
• W60939811 hasRelatedWork W2018585805 @default.
• W60939811 hasRelatedWork W2027922695 @default.
• W60939811 hasRelatedWork W2035301649 @default.
• W60939811 hasRelatedWork W2048381379 @default.
• W60939811 hasRelatedWork W2154005339 @default.
• W60939811 hasRelatedWork W2320029782 @default.
• W60939811 hasRelatedWork W2417414779 @default.
• W60939811 hasRelatedWork W2790353319 @default.
• W60939811 hasRelatedWork W1563323375 @default.
• W60939811 hasVolume "125" @default.
• W60939811 isParatext "false" @default.
• W60939811 isRetracted "false" @default.
• W60939811 magId "60939811" @default.
• W60939811 workType "article" @default.